Clinical Features and T‐Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC ‐ TFR Study

Documenti analoghi

• IFN‐α treatment may enable discontinuation of TKIs in NK cell‐licensed patients with CML‐CP
  di: Hiroshi Ureshino, et al.
  Pubblicazione: (2024)
• Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia
  di: Fiona Fernando, et al.
  Pubblicazione: (2025)
• An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies
  di: Akash Joel Sekar, et al.
  Pubblicazione: (2026)
• Treating Hematological Malignancies With OR ‐2100, an Orally Bioavailable Prodrug of Decitabine
  di: Tatsuro Watanabe, et al.
  Pubblicazione: (2025)
• Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia
  di: Ayca Irgit, et al.
  Pubblicazione: (2025)